Acute ischemic stroke is a common cause of morbidity and mortality worldwide.
Thrombolysis with recombinant tissue plasminogen activator and endovascular …

Ischemic stroke, a major cause of mortality in the United States, often contributes to
disruption of the blood-brain barrier (BBB). The BBB along with its supportive cells …

Recanalization therapy is increasingly used in the treatment of acute ischemic stroke.
However, in about one third of these patients, recanalization is followed by …

Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

Inflammation is an innate immune response to infection or tissue damage that is designed to
limit harm to the host, but contributes significantly to ischemic brain injury following stroke …

The blood-brain barrier (BBB) is a vital component of the neurovascular unit (NVU)
containing tight junctional (TJ) proteins and different ion and nutrient transporters which …

Brain ischemia is one of the leading causes of disability and mortality worldwide. Nitric oxide
(NO•), a molecule that is involved in the regulation of proper blood flow, vasodilation …

Background and Purpose—Although several clinical studies suggested the beneficial effects
of edaravone in acute ischemic stroke, most were performed under settings that differ from …

Ischemic stroke is a major cause of death and disability worldwide. The poor drug delivery to
cerebral ischemic regions remains a challenging issue for ischemic stroke treatment …

Tissue plasminogen activator (tPA) administered within 4.5 h of symptom onset restores
cerebral blood flow (CBF) and promotes neurological recovery of stroke patients. However …